OBJECTIVE: To determine whether administration of Lactobacillus reuteri (L reuteri) DSM 17938 is beneficial in breastfed infants with infantile colic. STUDY DESIGN:Eighty infants aged <5 months with infantile colic (defined as crying episodes lasting 3 or more hours per day and occurring at least 3 days per week within 7 days prior to enrollment), who were exclusively or predominantly (>50%) breastfed were randomly assigned to receive L reuteri DSM 17938 (10(8) colony-forming units) (n = 40) or an identically appearing and tasting placebo (n = 40), both orally, in 5 drops, 1 time daily, for 21 days. The primary outcome measures were the treatment success, defined as the percentage of children achieving a reduction in the daily average crying time ≥ 50%, and the duration of crying (minutes per day) at 7, 14, 21, and 28 days after randomization. RESULTS: The rate of responders to treatment was significantly higher in the probiotic group compared with the placebo group at day 7 (P = .026), at day 14 (relative risk (RR) 4.3, 95% CI 2.3-8.7), at day 21 (RR 2.7, 95% CI 1.85-4.1), and at day 28 (RR 2.5, 95% CI 1.8-3.75). In addition, throughout the study period, the median crying time was significantly reduced in the probiotic group compared with the control group. CONCLUSION: Exclusively or predominantly breastfed infants with infantile colic benefit from the administration of L reuteri DSM 17938 compared with placebo.
RCT Entities:
OBJECTIVE: To determine whether administration of Lactobacillus reuteri (L reuteri) DSM 17938 is beneficial in breastfed infants with infantile colic. STUDY DESIGN: Eighty infants aged <5 months with infantile colic (defined as crying episodes lasting 3 or more hours per day and occurring at least 3 days per week within 7 days prior to enrollment), who were exclusively or predominantly (>50%) breastfed were randomly assigned to receive L reuteri DSM 17938 (10(8) colony-forming units) (n = 40) or an identically appearing and tasting placebo (n = 40), both orally, in 5 drops, 1 time daily, for 21 days. The primary outcome measures were the treatment success, defined as the percentage of children achieving a reduction in the daily average crying time ≥ 50%, and the duration of crying (minutes per day) at 7, 14, 21, and 28 days after randomization. RESULTS: The rate of responders to treatment was significantly higher in the probiotic group compared with the placebo group at day 7 (P = .026), at day 14 (relative risk (RR) 4.3, 95% CI 2.3-8.7), at day 21 (RR 2.7, 95% CI 1.85-4.1), and at day 28 (RR 2.5, 95% CI 1.8-3.75). In addition, throughout the study period, the median crying time was significantly reduced in the probiotic group compared with the control group. CONCLUSION: Exclusively or predominantly breastfed infants with infantile colic benefit from the administration of L reuteri DSM 17938 compared with placebo.
Authors: Nicole Y Fatheree; Yuying Liu; Michael Ferris; Melissa Van Arsdall; Valarie McMurtry; Marcela Zozaya; Chunyan Cai; Mohammad H Rahbar; Manouchehr Hessabi; Ta Vu; Christine Wong; Juleen Min; Dat Q Tran; Fernando Navarro; Wallace Gleason; Sara Gonzalez; J Marc Rhoads Journal: World J Gastrointest Pathophysiol Date: 2016-02-15
Authors: Hanne Jensen; Stefan Roos; Hans Jonsson; Ida Rud; Stine Grimmer; Jan-Peter van Pijkeren; Robert A Britton; Lars Axelsson Journal: Microbiology (Reading) Date: 2014-01-28 Impact factor: 2.777
Authors: Christian Milani; Sabrina Duranti; Francesca Bottacini; Eoghan Casey; Francesca Turroni; Jennifer Mahony; Clara Belzer; Susana Delgado Palacio; Silvia Arboleya Montes; Leonardo Mancabelli; Gabriele Andrea Lugli; Juan Miguel Rodriguez; Lars Bode; Willem de Vos; Miguel Gueimonde; Abelardo Margolles; Douwe van Sinderen; Marco Ventura Journal: Microbiol Mol Biol Rev Date: 2017-11-08 Impact factor: 11.056
Authors: Chandrika J Piyathilake; Nicholas J Ollberding; Ranjit Kumar; Maurizio Macaluso; Ronald D Alvarez; Casey D Morrow Journal: Cancer Prev Res (Phila) Date: 2016-03-02